Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Non-Small Cell Lung Cancer 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroblastoma 1 Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Histiocytosis 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Trastuzumab 243 Paclitaxel 193 Cyclophosphamide 158 Docetaxel 134 Letrozole 113 Capecitabine 113 Fulvestrant 106 Doxorubicin 103 Bevacizumab 87 Carboplatin 81 exemestane 80 Anastrozole 79 Lapatinib 70 Tamoxifen 69 Albumin-Bound Paclitaxel 57 palbociclib 54 pertuzumab 53 Taxes 51 Gemcitabine 50 Radiotherapy 46 eribulin 43 pembrolizumab 41 Everolimus 41 Ado-Trastuzumab Emtansine 41 Vinorelbine 38 130-nm albumin-bound paclitaxel 35 ixabepilone 32 Epirubicin 28 pegfilgrastim 25 liposomal doxorubicin 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Breast Neoplasms × Antibodies × Clear all

NCT03280563 2025-11-10

MORPHEUS HR+BC

Hoffmann-La Roche

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡